Axon degeneration leads to cytoskeletal disassembly, metabolism imbalance, and mitochondrial dysfunction during neurodegeneration or nerve injury. OBJECTIVE: In this study, we assess the possibility of mitigating axon degeneration by local injection of mitochondria in a crushed sciatic nerve. METHODS: Sciatic nerve explants cocultured with mitochondria were assessed for the optimal dosage in local injection and nerve regeneration potential. The left sciatic nerve was crushed in Sprague-Dawley rats and then local injection of mitochondria into the distal end of the injured nerve was conducted for further assessment. RESULTS: Mitochondrial coculture attenuated cytoskeletal loss and oxidative stress in isolated nerve explants. In Vivo analyses also showed that mitochondrial transplantation improved animal neurobehaviors, electrophysiology of nerve conduction, and muscle activities. Mitochondria injection significantly attenuated the oxidative stress and increased the expression of neurotrophic factors both in injured nerves and denervated muscles, as well as restored muscular integrity, and increased the pool of muscular progenitor cells and total muscle weight. CONCLUSION: Mitochondria injection can protect injured nerves from axonal degeneration both in Vitro and in Vivo. This improvement was accompanied with the expression of neurotrophic factors as well as the reduction of oxidative stress, which may account for the functional recovery of both injured nerves and denervated muscles.
energy depletion. The energy impairment was mainly caused by supraphysiological calcium, released from the endoplasmic reticulum and mitochondria, and then activating catastrophic biochemical cascades such as high calpain and caspase activity, contributing to cell autophagy, cell apoptosis, and necrosis. [2] [3] [4] In addition, insufficient neurotrophic factors were also related to low activity of mitochondria, poor neural survival, and axon degeneration. 5, 6 This evidence indicates that disrupted mitochondria is highly associated with the pathogenesis of axon degeneration. 7 Mitochondrial dysfunction is associated with axon degeneration in many ways. First, nicotinamide mononucleotide adenylyltransferase (NMNAT3), a well-known neural protector, is localized in mitochondrial matrix. Damaged mitochondria reduce the activity of NMNAT3, the synthesis of nicotinamide adenine dinucleotide (NAD + ), and the integrity of the respiratory complex, which leads to the low production of energy pathways and an imbalance of intracellular redox status. [8] [9] [10] In addition, damaged mitochondria will generate high levels of reactive oxygen species and render lethal oxidative stress in neurons and glial cells. Third, injured mitochondria will open mitochondrial permeability transition pore and release proapoptotic factors, such as cytochrome c, apoptosis-inducing factor, Direct IAP binding protein with low pI (DIABLO) and endo G, to induce cell death and axon degeneration. 11, 12 Mitochondrial transfer offers a new hope in the treatment of diseases in which there is mitochondria dysfunction. 13, 14 Accumulative evidence indicates that human mesenchymal stem cells can restore mitochondria function in mitochondria-damaged cells by mitochondrial transfer. 15 In addition, local injection of isolated mitochondria into the damaged lung, heart, liver can restore the injured organ function. [16] [17] [18] Furthermore, the delivery of mitochondria with cell penetrating peptides can enhance the mitochondria uptake ratio and efficiently restore the respiratory function of fibroblasts from myoclonic epilepsy with ragged red fibers syndrome. 19 As noted, axonal degeneration is highly correlated to the dysfunction of mitochondria. Thus far, there were few reports concerning the local injection of mitochondria into the injured nerve to assess the potential of prevention of axon degeneration. In this study, we conducted the nerve explants coculture system to assess the optimal dosage of isolated mitochondria for reducing radical oxygen response. In animal study, we injected the mitochondria into the perineurium of crushed nerve to evaluate the mitochondrial effects on functional recovery of neurobehavior, molecular profiles of neural degeneration/regeneration, and histopathology of nerve and muscle. This study will shed light on the potential of mitochondrial transplantation for the treatment of peripheral nerve injury in human beings.
METHODS
All of the experimental protocols were approved by the Taichung Veterans General Hospital, and all animals were treated and cared for in accordance with the guidelines recommended by the Institutional Animal Care and Use Committee (IACUC) of Taichung Veterans General Hospital (La-1041314).
Construction of mitoGFP-BHK Cells
For tracking mitochondria after transplantation, we transfected Green fluorescent protein (GFP) with mitochondrial signal peptide to baby hamster kidney fibroblast cells (BHK-21 cells). The cellular constitutive expression of GFP-tagged mitochondria (mitoGFP-BHK cells) was selected by G418 antibiotics and cell sorting. The mitoBHK-GFP cells were cultured in high-glucose Dulbecco's modified Eagle's medium (DMEM) supplemented with 5% fetal bovine serum (FBS), 1% penicillin and streptomycin (P/S), 1 mM L-glutamine and 1 mM nonessential amino acids.
Extraction of GFP-labeled Mitochondria From mitoGFP-BHK Cells
Dissociated 2 × 10 8 mitoGFP-BHK cells were washed with phosphate-buffered saline (PBS) and suspended with 2 ml soluble epoxide hydrolase (SEH) buffer (0.25 M sucrose, 0.5 mM ethylene glycol tetraacetic acid, 3 mM N-(2-Hydroxyethyl) piperazine-N'-ethanesulfonic acid, pH 7.2; all from Sigma-Aldrich [St. Louis, Missouri]). Over 90% of the cells were homogenized and disrupted by 25 to 30 strokes of the pestle in 10 ml Dounce grinders (Wheaton, Millville, New Jersey). The crude lysates were centrifuged at 1000× g (Tomy Digital Biology, MX-301, Tokyo, Japan) for 15 min, and their supernatants were collected. Further centrifugation at 9000× g (Tomy Digital Biology) for 15 min concentrated the mitochondria from the supernatant in a pellet, and the concentrate was used in the following study.
Sciatic Nerve Explants Culture
The sciatic nerve was harvested from Sprague-Dawley rats, and these nerves were cut into 3-mm lengths and cultured in calcium/magnesiumfree Hanks' Balanced Salt Solution (HBSS). Under the microscope, the nerve tissue was separated from the surrounding connective tissues and only the single bundle of nerve tissue was used for analysis. For the determination of optimal dosage of mitochondria in transplantation, gradient concentrations of mitochondria, ranging from 0, 65, 130, 195 to 269 μg, were cocultured with the sciatic nerve in the medium of DMEM with 10% FBS and 5% P/S at the condition of 5% CO 2 and 37
• C for 1 to 3 days. The nerve tissue was fixed with 4% paraformaldehyde for 6 h and observed under the light microscope. The ovoid number in each 500 μm of nerve was calculated for the quantitative analysis.
Nerve Crush Model
Sprague-Dawley rats weighing 250 to 300 g were anesthetized with 4% isoflurane in induction and kept under a maintenance dose (1%-2%). The left sciatic nerve was exposed under a microscope using the gluteal muscle splitting method. The left sciatic nerve was crushed at the point of 10 mm from the obturator by a vessel clamp (B-3, pressure 1.5 g/mm 2 , S&T Marketing Ltd, Neuhausent, Switzerland) for 20 min. 20 After the nerve injury, the animals were assigned into 1 of 2 groups as follows: group I, nerve crush as a control with 100 μl PBS perineurium injection (control group); group II, nerve crush with 195 μg mitochondria perineurium injection as an experimental group (Mito group). One hundred ninety-five μg of mitochondria diluted in PBS with final volume of 100 μl was injected into the epineurium 10 mm distal to the crushed site within 10 min using a 31-gauge Hamilton syringe attached to an automated pump and left in situ for an additional 3 min to avoid reflux along the injection tract. All animals received rehabilitation therapy on a metal mesh every week. Food and water were provided ad libitum before and after the experiments. The animals were kept in a temperature-controlled environment at 20
• C, and they were exposed to alternating light and dark cycles of 12-h intervals. All animals were treated and cared for in accordance with the guidelines recommended by the IACUC of Taichung Veterans General Hospital. The animals received neurological assessment weekly after operation until the end of the experiment and then were subjected to histological and electrophysiological assessments at 1 month postoperation. Then, retrograde neuronal tracing was conducted for 6 animals in each group at 1 month after operation. In the in Vivo short-term assessment of mitochondria injection to prevent the nerve degeneration, the same animal treatment procedure as depicted above was followed. These animals were sacrificed at 1 and 3 days after injury and subjected to morphology, cholera toxin subunit B (CTB) tracing, and electrophysiological assessment.
Analysis of Motor Function of Sciatic Nerve-injured Rats
The animal care staff members were blinded to the animal group assignment. Sciatic nerve function was analyzed by the sciatic function index (SFI) at preoperative stage and every week postsurgery. Several parameters were obtained from the footprint, and these included the following: (i) distance from the heel to the third toe, the print length (PL); (ii) distance from the first to the fifth toe, the toe spread (TS); and (iii) distance from the second to the fourth toe, the intermediary toe spread (ITS). All three measurements were taken from the experimental (E) and normal (N) sides. The SFI was calculated according to the equation below: SFI = 38.3(EPL − NPL/NPL) + 10.9(ETS − NTS/NTS)
The SFI ranges from 0, which indicates normal nerve function, to -100, which represents total function impairment.
Von Frey Test
Mechanical allodynia was assessed by using Von Frey hair (TouchTest Sensory Evaluator, North Coast Medical, Inc., Gilroy, California), as previously described in our group. 21 The method of allodynia assessment was modified by the previous procedure. Each experimental rat was placed alone in a customized transparent acrylic chamber (20 × 20 × 20 cm) with a 5-mm thick acryl platform. In every trial of allodynia assessment, Von Frey hair in different amounts (grams) was applied serially to the bilateral hind paw 5 times at 5 s intervals or at the moment the hind paw was placed appropriately on the platform. If tested rats did not withdraw the hind paw during 5 applications of a hair, the next larger hair was applied. The withdrawal threshold depended on the value (gram) of the hair which caused the hind paw withdrawal either 4 or 5 times out of the 5 applications. 
CatWalk Gait Analysis
The methodology in conducting the CatWalk gait analysis has been previously described. 21 In brief, the CatWalk XT system (Noldus, Wageningen, The Netherlands) comes with a high-speed digital camera with a sampling rate of 100 frames per second. The video camera transforms each scene (ie, the area in front of the lens) into a digital image (ie, an image composed of discrete pixels of digital brightness values). The brightness of a pixel depends on the amount of light received from such an area by the camera. The illuminated Footprint enables intensity difference to be detected between animals' paws. The intensity varies from 0 to 225, and they are represented by different colors. Quantitative analysis of the data from the CatWalk XT included the following parameters: step sequence distribution, regularity index, print area, duration of swing and stance phases, and footprint intensity.
Electrophysiological Assessment
Sciatic nerve from each group was exposed at 1 day, 3 days, and 1 month after experiment, and electrical stimulation was applied to the proximal side of the injured nerve. The compound muscle action potential (CMAP) amplitudes and conduction latencies were recorded in the gastrocnemius muscle with an active monopolar needle electrode 10 mm below the tibia tubercle and with a reference needle 20 mm from the active electrode. The stimulation intensity and filtration ranges were 5 mA and 20 to 2000 Hz, respectively. A similar procedure was conducted on the noninjured side. The CMAP and conduction latency data were converted to the ratio of the injured side divided by the normal side to adjust for the effect of anesthesia.
Retrograde Neuronal Labeling
We assessed the integrity of proximal nerve fibers from motor neurons and dorsal root ganglion neurons by applying cholera toxin subunit B (List Biological Laboratories, Campbell, California, USA). The CTB capsule was placed at the cut end of sciatic nerve 1 cm distal to the crush site. The capsule was left in place for 30 min and then was removed. The surrounding area of the crush site was rinsed with normal saline. At 24 h postlabeling, these animals (6 rats for each group) were deeply anesthetized again and perfused via the ascending aorta with 200 ml saline at body temperature, followed by 700 ml of ice-cold 4% (W/V) paraformaldehyde (pH 7.2-7.4). The L5 spinal cord segment and associated dorsal root ganglion were carefully removed. The L5 spinal cord was postfixed for 4 h and cryoprotected in 30% sucrose (pH 7.3) at 4
• C overnight. Frozen cross sections were cut at 20 mm with Cryostat (Leica CM 3050S, Nussloch, Germany). Every fifth section was thaw mounted serially in a rostrocaudal sequence on gelatin-coated slide, and values were determined by the pixel of every imaging. In the short-term assessment of CTB travelling, 8 h after CTB soaking, the nerve was harvested to assess the travelling distance. The data were presented as the distance of CTB distribution measured from the crushed site.
Western Blot Analysis
The nerve explants culture, the middle part of the gastrocnemius muscle, and distal end of the crushed nerve were harvested, and the proteins were extracted. Proteins (50 μg) were resolved by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis and transferred onto a blotting membrane. After blocking with nonfat milk, the membranes were incubated with antibodies against 8-oxo-dG (1:1000, R&D Systems Inc., Minneapolis, Minnesota), S-100 (1:1000, Serotek, Minneapolis, Minnesota), neurofilament (1:1000, EDM Millipore, Merck KGaG, Darmstadt, Germany), CD 68 (1:1000 Chemicon, Temecula, California), NT-3 (1:1000, Millipore), brain-derived neurotrophic factor (BDNF) (1:1000, abcam, Cambridge, United Kingdom), Ciliary neurotrophic factor (CNTF) (1:1000, Abbiotec, San Diego, California), GDNF (1:1000, Abbiotec), desmin (1:1000, Proteintech, Rosemont, Illinois), acetylcholine receptor (1:1000, Millipore), Pax 3(1:1000, Abbiotec), Pax 7(1:1000, BioSS, Edinburgh, Scotland), GAP-43(1:000, BD transduction, BD Biosciences, San Jose, California), Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (1: 2000, Santa Cruz Biotechnology, Dallas, Texas) overnight at 4
• C. The membranes were incubated with horseradish peroxidase-conjugated secondary antibody and developed using Enhanced chemiluminescence (ECL) western blotting reagents. The intensity of protein bands was determined by a computer image analysis system (IS1000, Alpha Innotech Corporation, San Leandro, California). 
Immunohistochemistry
The nerve explants culture, the middle part of the gastrocnemius muscle, and distal end of the crushed nerve were cryosectioned into 8 μm and mounted on superfrost/plus slides (Menzel-Glaser, Braunschweig, Germany). The tissue slices were subjected to immunohistochemistry with antibodies against neurofilament 
Histology Examination
After behavioral and electrophysiological examination, 6 rats in each group were subjected to transcardial perfusion with 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4). The weight of bilateral gastrocnemius muscle was measured. Left sciatic nerve and muscle were harvested from the animals after electrophysiological assessment, and the nerve tissue was fixed on a plastic plate using stay suturing to keep the nerve straight. The nerve and muscle were embedded, cut longitudinally into sections 8-μm thick, and examined with hematoxylin-eosin (H&E) and immunohistochemical stainings.
Statistical Analysis
Data were presented as mean ± standard error. The statistical significance of differences between groups was determined by one-way analysis of variance (ANOVA) followed by Dunnett's test. For SFI and CatWalk analysis, and Von-Frey test, the results were analyzed by repeated measurement of ANOVA followed by Bonferroni's multiple comparison method. A P value less than .05 was considered to be significant.
RESULTS

Assessment of Potentiation of Mitochondria in Prevention of Axon Degeneration in Explants Nerve Culture
To evaluate the optimal dosage of mitochondria in the treatment of nerve crush injury, we cocultured sciatic nerve explants with different dosages of mitochondria, ranging from 0, 65, 130, 195 to 269 μg, and assessed the degeneration status by calculation of ovoid number and oxidative stress by 8-oxo-dG. We found that the ovoid number of axon was reduced by the escalated dosage of mitochondria from 0 to 195 μg. Providing 269 μg of mitochondria did not show enhanced protective effects beyond that of 195 μg of mitochondria ( Figures 1A-F) . The decreased density expression of 8-oxo-dG was related to increased dosage of mitochondria, but the dosage of 269 μg also cannot further augment this antioxidative response ( Figures 1G-K) . The trends of western blot analysis of 8-oxo-dG further confirmed this phenomenon ( Figure 1L ). Hence, we used the dosage of 195 μg in the following study.
We first demonstrated that 195 μg of GFP-tagged mitochondria were engrafted by perineum injection into the sciatic nerve and showed extensive distribution in the nerve fibers when compared to PBS injection as a control (Figures 1M-P) .
To determine the influence of oxidative stress related to nerve regeneration/degeneration, the nerve explants were cocultured with mitochondria subjected to analysis of 8-oxo-dG and neurofilament at different time profiles. At day 1, we found that there was high expression of neurofilament with reciprocally decreased expression of 8-oxo-dG after mitochondria treatment. Up to day 3, the result of nerve explants also showed the same trends (Figures 2A and B) . In the quantitative analysis by western blot assessment ( Figure 2C) , the results were also in the line with those in immunohistochemistry staining ( Figure 2D) . Hence, the oxidative stress-triggered neurofilament (NF) damage in nerve explants was rescued by the administration of mitochondria. 
FIGURE 6. Representative of CTB distributed from the proximal nerve to anterior horn cells. A, B, Distribution of CTB in proximal nerve in control and mitochondria group. C, D, Distribution of CTB in dorsal root ganglion in control and mitochondria group. E, F, Distribution of CTB in anterior horn
Attenuation of Nerve Degeneration Subjected to Mitochondria Injection in the Early Period of Nerve Injury
It is not clear to what extent the beneficial effects of supplemental mitochondria are due to reducing the immediate and primary effect of crush nerve injury to the nerve and to what extent they are due to reversing later occurring events both during the degeneration and regenerative phase of nerve injury. We conducted short-term (1 and 3 days after injury) in Vivo study of morphology of nerve structure, axon transport, and the electrophysiology to clear this debate. In the morphology analysis, the increased ovoid number of nerve fibers was observed either at 1 or 3 days after crush and attenuated by the administration of mitochondria (Figures 3A and B) . The distance of cholera toxin subunit B (CTB) travelling was attenuated after crush and the restoration of the travelling was noted after mitochondria injection ( Figures 3C and 3D ). The amplitude of CMAP was reduced after crush and augmented by mitochondria injection ( Figure 3E ). The conduction latency was prolonged after crush and speeded by mitochondria injection ( Figure 3F) . The above study revealed that the mitochondria injection prevented axon degeneration and provided the basis for the later regeneration.
Improved Neurobehavior in Crushed Nerve Injury by the Administration of Mitochondria
In SFI gait analysis, we found that nerve crush causes a significant decrease of SFI at day 7 and had the potential of spontaneous recovery up to day 28. The mitochondria injection can maintain high SFI function even at day 7 as compared to the control group. For up to 28 days, the SFI recovered to near normal. The statistical analysis showed a significant improvement after mitochondria administration (P < .001; Figure 4A ). Twenty-eight days after nerve injury, the electrophysiological study revealed the significant improvement in mitochondria group either in CMAP (P < .05) and conduction latency (P < .05; Figures 4B and C) . The Von Frey test also showed an increased pain threshold at day 7 after nerve crush and then with progressive improvement up to day 28. The administration of mitochondria alleviated the pain behavior from 7 to 28 days as compared to the control group (P < .001; Figure 4D ).
The histology of sciatic nerves after mitochondria treatment was assessed on day 28 after injury. The vacuoles formation within the sciatic nerve tissues, a classical pathological feature of nerve degeneration, was significantly attenuated after mitochondria administration ( Figures 4E and F) . The mitochondria-treated nerve explants showed an increased expression of S-100, a mature schwann cell marker, compared to the nontreated control ( Figures 4G and H) .
Long-term denervation causes little release of neurotrophic factors from nerve terminals to myofibers and results in muscle atrophy and muscle weight loss. Histological examination revealed that a larger diameter of muscle fibers was observed after administration of mitochondria than that of the nontreated denervated muscle on day 28 postoperation (Figures 4I and J) . In addition to the preservation of muscle morphology, muscle weight was regained in the mitochondria-treated group (P < .05; Figure 4K ).
In addition to SFI examination, CatWalk gait analysis provides more detailed information about motor activities of tested animals. In CatWalk gait analysis, the ratio of printed area was decreased to the bottom at day 7 and then progressively improved up to day 28. The mitochondria injection not only abolished the decrease previously observed at day 7, but also showed a significant improvement compared to the control group (P < .05; Figure 5A ). There was increased swing ratio up to 2 fold at day 7 after nerve crush and then a progressive decrease up to 28 days. The administration of mitochondria maintained the ratio about 1.4 fold at day 7 and reached a value near base line at 28 days. The trend between the 2 groups revealed a significant difference (P < .05; Figure 5B ). In stand gait analysis, the data showed a reciprocal trend related to the data of swing phase (P < .05; Figure 5C ). The ratio of swing speed was highly correlated to the trend in the stand phase, which indicated the increased swing speed in the mitochondria treatment as compared to the control (P < .05; Figure 5D ).
Examining the nerve integrity by CTB retrograde labeling revealed that nontreated control group showed little deposit of CTB in the proximal end of nerve, dorsal root ganglion, and anterior horn cells on day 28 postoperation (Figures 6A-F) . Transplanting mitochondria significantly enhanced the accumulation of retrograded CTB in the proximal peripheral nerve, sensory and motor neurons (P < .001, P < .05, P < .05, respectively; Figure 6G ), indicating that engrafted mitochondria successfully rescued the axon degeneration and restored the capability of axon traffic.
Increased Nerve Regeneration and Reduced Oxidative Stress by Mitochondria Treatment
The therapeutic effects of mitochondria on rats with crushed sciatic nerve were investigated in the harvested nerve on day 7 postoperation. As the results of mitochondria-treated nerve explants ex Vivo, engrafting the mitochondria restored the expression of neurofilament (NF) and S-100 and attenuated the 8-oxo-dG contents in the crushed nerves (Figures 7A-D) . We also found that accumulated CD68 + inflammatory cells were distributed in the crushed nerves, but the inflammatory cells were significantly alleviated after mitochondria treatment ( Figures 7E  and F) . The representative of 8-oxo-dG from the distal, crush, and proximal end of nerve subjected to mitochondria treatment was illustrated in Figure 7G . The expression of neurofilaments, S-100, and CD 68 were shown in Figures 7H and I . Taken together, these results demonstrate that providing mitochondria mitigates the oxidative stress and the secondary inflammatory response in the damaged sciatic nerves.
The low expression of neurotrophic factors is a hallmark of nerve degeneration. The decreased expression of neurotrophic factors, including NT-3, CNTF, BDNF, and GDNF, was found on day 7 after nerve crush. The increased expression of the neurotrophic factors was detected in the mitochondria treatment group (Figures 8A-H) . The results of western blot analysis also showed the same trend as those findings observed with the immunohistochemical staining ( Figure 8I ). The expression of neurotrophic factors showed significant difference between control and mitochondria group, including the expressions of NT-3 (P < .001), CNTF (P < .001), BDNF (P < .001), and GDNF (P < .001; Figure 8J ). The above data demonstrated that the mitochondria can rescue the axon degeneration and increase the nerve regeneration potential.
Protection of Muscle Denervation by Mitochondria Injection
Terminal axon degeneration by nerve crush caused the loss of neuromuscular junctions on myofibers, revealed by the deprivation of acetylcholine receptor and desmin, on day 7 postoperation. The mitochondria treatment significantly rescued the expressions of acetylcholine receptor and desmin in the denervated muscles (P < .01; Figures 9A-D) . The high 8-oxo-dG signals were also noted in denervated muscle after nerve crush ( Figures 9E and F) . Corresponding to the results of nerve explants ex Vivo, this strong oxidative stress was dramatically attenuated by the mitochondria treatment (P < .01; Figures 9G and H) .
Both low neurotrophic factors and loss of myosatellite cells may contribute to the denervation-induced muscle atrophy. We demonstrated that the number of myosatellite cells, revealed by the Pax3, Pax7, and GAP-43 expression, was downregulated after nerve crush injury. Increased expressions of Pax3, Pax7, and GAP-43 were observed after the mitochondria treatment ( Figures 10A-F) . In addition, we also demonstrated that mitochondria transplantation maintained the neurotrophic factor contents in the denervated muscles, such as the BDNF and CNTF (Figures 10G-J) .
The western blot analysis further demonstrated that mitochondrial engraftment significantly rescued the expressions of Pax3 (P < .01), Pax7 (P < .001), and GAP-43 (P < .001) in denervated muscle, indicating that the reduced population of myosatellite 
DISCUSSION
Axonal mitochondrion is an early sensor and modulator for axon degeneration in central nervous system (CNS) and peripheral nervous system (PNS). 7 Dysregulated dynamics of mitochondria is a hallmark of axon degeneration in several human inherent neural diseases. Maintaining the numbers and integrity of mitochondria in the terminal axons by chemicals attenuates axonal destruction and secondary inflammation. 13, 14, 18 Recent evidence also indicates that reduced mitochondria numbers result in axon degeneration in Caenorhabditis elegans. 22 Here, we provided the first evidence demonstrating that supplement of mitochondria can successfully prevent peripheral nerve injury and denervated muscle atrophy. Our results showed that mitochondria injection into the injured nerve reduced the oxidative stress and augmented the nerve regeneration ex Vivo and in Vivo.
Degeneration of axon causes the fragment of the myelin sheath into the small ovoid structure. 23 The restoration of degeneration process was highly related to decreased ovoid number in the demyelination process. 24 The expression of 8-oxo-dG was upregulated in injured nerve and muscle, which was likely related to severity of nerve injury and intensity of oxidative stress. 25 In this study, we first demonstrated that the decreased ovoid number of sciatic nerve explants was in line with the dosage of cocultured mitochondria. This phenomenon was reciprocal related to the reduced expression of 8-oxo-dG and upregulated expression of neurofilaments of the nerve explants. Thus, the supplement of extracellular mitochondria in injured nerve can protect the nerve from the degeneration process.
There were several neurobehavioral assessments including sciatic nerve function index, CMAP, nerve conduction latency, which were highly correlated to the histomorphological alteration and expression of regeneration markers. 20, 25 In addition, the CatWalk gait analysis showed a high correlation to subtle alteration of neurobehavioral alteration, 26 and this alteration was in line with severity of nerve injury and animal pain behavior. 25 In addition to the nerve explants coculture, mitochondria was transplanted into the perineurium of rats with sciatic nerve injury and showed a strong potency of antioxidation, anti-inflammation, and tissue regeneration activities. The nerve tissue restoration contributed to the sensory and motor functional recovery, assessed by Von-Frey test, SFI, CMAP, nerve conduction latency, and CatWalk gait analysis. Although the detailed mechanisms of neural protection are still largely obscured, we demonstrated that mitochondria transplantation restored the expression of neurotrophic factors in the injured sciatic nerves and in the denervated muscles. The injection of mitochondria restored both the nerve myelination and the expression of neurotrophic factors in the injured nerve, such as GDNF, BDNF, NT-3, and CNTF. 20, 25, 27, 28 In addition to nerve regeneration, the recovery of myofiber size and the acetylocholine receptor and desmin expression in muscle further emphasize the nerve regeneration in the denervated muscle of the mitochondria-treated rats which was compatible with the regeneration potential. 20, 25, 29 Interestingly, we illustrated that Pax3/Pax7 positive myosatellite progenitor cells were also restored in the denervated muscles after the mitochondria treatment. These results confirmed the regeneration of nerve and muscle initiated by mitochondria injection. We argue that the significantly elevated neurotrophic factor contents may account for, at least in part, the attenuated degeneration process of the nerve and muscle. 5, 6 Upon nerve crush, the distal end of injured nerve will undergo Wallerian degeneration. Based on the assumption of mitochondria to rescue injured nerve from degeneration, we proposed to inject mitochondria into the distal site of crushed nerve to assess the potentiation against the nerve degeneration. In addition, we attempted to attenuate the confounding factors from the operation by the clamp especially in the morphology and protein analysis. Hence, it is reasonable to inject the mitochondria to distal end of crushed nerve in this study.
It will be interesting to further investigate how extracellular mitochondria ameliorate the cellular degeneration of the nerve explants. Although highly myelinated Schwann cells ensheathing the nerve may lose their capacity to uptake the cocultured mitochondria, nonmyelinated Schwann cells may phagocytose the isolated mitochondria and maintain the cell survival during the nerve degeneration. In addition, nonphagocytosed mitochondria may provide adenosine triphosphate (ATP) to Schwann cells and the mitochondria per se can be an oxidative buffer for attenuating nerve degeneration. Furthermore, it is critical to further clarify whether the engrafted mitochondria could be transported to the terminal axons and be responsible for the rescue of motor activities. Discriminating these potential protective pathways will elucidate the underlying mechanisms of the mitochondria-mediated protection on peripheral nerve injury. We also argue that enhancing the uptake efficacy and transportation within the axons will benefit the therapeutic effects of mitochondria treatment.
CONCLUSION
Perineurium injection of mitochondria may be a potential treatment in nerve degenerative disorder. In this study, we found that mitochondria treatment exerted significantly decreased oxidative stress in injured nerve and increased nerve regeneration. In addition, the increased neurotrophic factors in nerve and muscle were in line with the improved outcome in neurological function.
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COMMENTS
A very interesting and provocative paper suggesting that supplemental mitochondria can mitigate and/or reverse many of the primary and secondary consequences following nerve injury in both nerve and muscle. The work suggests that nerve degeneration can be significantly modified by injections of mitochondria into nerve distal to a crush site so that ovoid formation is reduced and axonal transport, nerve conduction,
